Buradasınız

Anasayfa » Content

Erişkin İmmun Trombositopeni ve Tedavisi: Derleme

Management of Adult Immune Thrombocytopenia: Review Article

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder defined by isolated thrombocytopenia and the exclusion of other causes of thrombocytopenia.Although the underlying pathophysiology of ITP has been known for more than five decades, therapy has remained empirical. ITP guidelines were published by the American Society of Hematology 15 years ago (updated in 2011) and the British Committee for Standards in Hematology 8 years ago. The primary treatment goal is to prevent severe bleeding rather than achieve normal platelet counts. Nowadays, new therapeutic agents have changed strategies for ITP treatment. In this review,we discuss criteria for treatment, the role of splenectomy and other treatment options along with their side effects, and the treatment of ITP during pregnancy.
Bookmark/Search this post with
Abstract (Original Language): 
İmmün trombositopeni (İTP) diğer trombositopeni yapan nedenlerin olmaması ve izole trombositopeni ile seyreden edinilmiş otoimmün hastalıktır. İTP’nın patofizyolojisi 50 yıldan daha uzun süredir bilinmesine rağmen tedavi empirik olarak kalmıştır. İTP kılavuzu 15 yıl önce Amerikan Hematoloji Derneği(2011 de güncellenmiştir) ve 8 yıl önce de Hematoloji Standartları İngiliz Komitesi tarafından yayınlanmıştır. Tedavinin başlıca amacı normal platelet sayısına ulaşıncaya kadar ciddi kanamayı engellemektir. Günümüzde İTP’de yeni ilaçlarla tedavi stratejileri değişti. Bu derlemede erişkin İTP’de tedavi kriterlerini, tedavi yaklaşımlarını, splenektominin rolünü, yan etkileri ile birlikte diğer tedavi seçeneklerini ve gebelikteki İTP’nın tedavisini tartıştık.
FULL TEXT (PDF): 
PDF icon arastirmax-eriskin-immun-trombositopeni-tedavisi-derleme.pdf
  • 3
203-212
  • Turkish

REFERENCES

References: 

1. Neunert C, Lim W, Crowther M, et. al. The American Society of
Hematology 2011 evidence-based practice guideline for immune
thrombocytopenia. Blood 2011; 21; 117(16): 4190-207.
2. Yang R, Han ZC. Pathogenesis and management of chronic
idiopathic thrombocytopenic purpura: an update. Int J Hematol
2000;71:18-24.
3. George JN, Woolf SH, Raskob GE, et. al.Idiopathic
thrombocytopenic purpura : A practice guideline developed by
explicit methods for the American Society of Hematology Blood
1996; 88:3-40.
4. British Committee for Standards in Haematology General
Haematology Task Force. Guidelines for the investigation and
management of idiopathic thrombocytopenic purpura in adults,
children and in pregnancy. Br J Haematol 2003; 120: 574-596.
5. Provan D, Stasi R, Newland AC, et. al. International consensus
report on the investigation and management of primaryimmune
thrombocytopenia Blood 2010 14; 115(2): 168-86.
6. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A,
Amadori S. Idiopathic thrombocytopenic purpura: current
concepts in pathophysiology and management. Thromb Haemost
2008; 99: 4-13.
7. Psaila B, Bussel JB. Immune thrombocytopenic purpura.
Hematol Oncol Clin North Am 2007; 21:743-59.
8. Cines DB, McMillan R. Pathogenesis of chronic immune
thrombocytopenic purpura. Curr Opin Hematol 2007; 14: 511-4.
9. Provan D, Newland A. Idiopathic thrombocytopenic purpura in
adults. J Pediatr Hematol Oncol 2003; 25: 1:4-8.
10. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic
purpura (ITP). Blood 2005; 1; 106: 2244-51.
11. Kaya E, Erkurt MA, Aydogdu I, et. al Retrospective analysis of
patients with idiopathic thrombocytopenic purpura from Eastern
Anatolia. Med Princ Pract 2007; 16: 100-6.
12. Portielje JE, Westendorp RG, Kluin-Nelemans HC, et. al.
Morbidity and mortality in adults with idiopathic
thrombocytopenic purpura. Blood 2001; 1;97: 2549-54.
13. Godeau B, Provan D, Bussel J. Immune thrombocytopenic
purpura in adults. Curr Opin Hematol 2007;14:535-56.
14. Rodeghiero F. First-line therapies for immune thrombocytopenic
purpura: re-evaluating the need to treat. Eur J Haematol Suppl
2008; 69: 19-26.
15. Boruchov DM, Gururangan S, Driscoll MC, et. al. Multiagent
induction and maintenance therapy for patients with refractory
immune thrombocytopenic purpura (ITP). Blood 2007; 110:
3526-31.
16. Kuku I, Aydogdu I, Kaya E, et. al. The early and long-term
results of oral high-dose methylprednisolone treatment in adult
patients with idiopathic thrombocytopenic purpura. Eur J
Haematol 2005; 74: 271-2.
17. Mazzucconi MG, Fazi P, Bernasconi S, et. al. Therapy with highdose
dexamethasone (HDDXM) in previously untreated patients
affected by idiopathic thrombocytopenic purpura: a GIMEMA
experience. Blood 2007; 109: 1401-7.
18. Stevens W, Koene H, Zwaginga JJ, et. al. Chronic idiopathic
thrombocytopenic purpura: present strategy, guidelines and new
insights. Neth J Med 2006; 64: 356-63.
19. Ismet A, Irfan K, Emin K, et. al. Splenectomy results in patients
with idiopathic thrombocytopenic purpura: 10 years of
experience in Turgut Ozal Medical Center. Clin Lab Haem 2004;
26: 211-4.
20. Pace DE, Chiasson PM, Schlachta CM, et. al. Laparoscopic
splenectomy for idiopathic thrombocytopenic purpura (ITP).
Surg Endosc 2003; 17: 95-8.
21. Cordera F, Long KH, Nagorney DM et. al. Open versus
laparoscopic splenectomy for idiopathic thrombocytopenic
purpura: clinical and economic analysis. Surgery 2003; 134: 45-52.
22. Lorton JE. Management of asplenic patients. Br J Haematol
1993; 84: 566-9.
23. George JN. Management of patients with refractory immune
thrombocytopenic purpura. J Thromb Haemost 2006; 4: 1664-
72.
24. Zhou Z, Yang R. Rituximab treatment for chronic refractory
idiopathic thrombocytopenic purpura. Crit Rev Oncol Hematol
2008; 65: 21-31.
25. Psaila B, Bussel JB. Refractory immune thrombocytopenic
purpura: current strategies for investigation and management. Br
J Haematol 2008; 143: 16-26.
26. Arnold DM, Dentali F, Crowther MA, et. al. Systematic review:
efficacy and safety of rituximab for adults with idiopathic
thrombocytopenic purpura. Ann Intern Med 2007; 21; 147:281.
27. Zaja F, Baccarani M, Mazza P, et. al. Dexamethasone plus
rituximab yields higher sustained response rates than
dexamethasone monotherapy in adults with primary immune
thrombocytopenia. Blood 2010; 8;115(14): 2755-62.
28. Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic
agents: a review of their use in idiopathic thrombocytopenic
purpura. Drugs 2008; 68(7): 901-12.
29. Kuter DJ, Bussel JB, Lyons RM, et. al. Efficacy of romiplostim in
patients with chronic immune thrombocytopenic purpura: a
double-blind randomised controlled trial. Lancet 2008;
371(9610):395-403.
30. Garvey B. Management of chronic autoimmune
thrombocytopenic purpura (ITP) in adults. Transfus Sci 1998; 19:
269-77.
31. Emilia G, Morselli M, Luppi M, et. al. Long-term salvage therapy
with cyclosporin A in refractory idiopathic thrombocytopenic
purpura. Blood 2002; 99: 1482-5.
32. Kotb R, Pinganaud C, Trichet C, et. al. Efficacy of
mycophenolate mofetil in adult refractory auto-immune
cytopenias: a single center preliminary study. Eur J Haematol
2005; 75:60-64.
33. Provan D, Moss AJ, Newland AC, et. al.. Efficacy of
mycophenolate mofetil as single-agent therapy for refractory
immune thrombocytopenic purpura. Am J Hematol 2006; 81:19-
25.
34. Howard J, Hoffbrand AV, Prentice HG, et. al. Mycophenolate
mofetil for the treatment of refractory auto-immune haemolytic
anemia and auto-immune thrombocytopenia purpura. Br J
Haematol 2002; 117: 712-15.
Erkurt et al.
212
35. Vesely SK, Perdue JJ, Rizvi MA et.al. Management of adult
patients with persistent idiopathic thrombocytopenic purpura
following splenectomy: a systematic review. Ann Intern Med
2004; 140: 112-120.
36. Damodar S, Viswabandya A, George B, et. al Dapsone for
chronic idiopathic thrombocytopenic purpura in children and
adults: a report on 90 patients. Eur J Haematol 2005; 75: 328-
331.
37. Godeau B, Durand JM, Roudot-Thoraval F, et. al. Dapsone for
chronic autoimmune thrombocytopenic purpura: a report of 66
cases. Br J Haematol 1997; 97: 336-9.
38. Manoharan A. Treatment of refractory idiopathic
thrombocytopenic purpura in adults. Br J Haematol 1991; 79:
143-7.
39. Berchtold P, McMillan R. Therapy of chronic idiopathic
thrombocytopenic purpura in adults. Blood 1989; 74: 2309-17.
40. Cines DB, McMillan R. Management of adult idiopathic
thrombocytopenic purpura. Annu Rev Med 2005; 56: 425-42.
41. Dubbeld P, Hillen HFP, Schouten HC. Interferon treatment of
refractory idiopathic thrombocytopenic purpura (ITP). Eur J
Haematol 1994; 52: 233-5.
42. Stasi R, Provan D. Management of immune thrombocytopenic
purpura in adults. Mayo Clin Proc 2004; 79: 456-7.
43. Emilia G, Luppi M, Torelli G. Infectious agents and human
immune diseases: lessons from Helicobacter pylori. Am J Med 2005;
118: 420-1.
44. Emilia G, Luppi M, Zucchini P, et. al. Helicobacter pylori
infection and chronic immune thrombocytopenic purpura: longterm
results of bacterium eradication and association with
bacterium virulence profiles. Blood 2007; 110: 3833-41.
45. Kohda K, Kuga T, Kogawa K, et. al. Effect of Helicobacter
pylori eradication on platelet recovery in Japanese patients with
chronic idiopathic thrombocytopenic purpura and secondary
autoimmune thrombocytopenic purpura. Br J Haematol 2002;
118: 584-8.
46. Michel M, Cooper N, Jean C, et. al. Does Helicobacter pylori
initiate or perpetuate immune thrombocytopenic purpura? Blood
2003;103: 890-96.
47. Gernsheimer T, McCrae KR. Immune thrombocytopenic
purpura in pregnancy. Curr Opin Hematol 2007; 14: 574-80.
48. Webert KE, Mittal R, Sigouin C et. al. A retrospective 11-year
analysis of obstetric patients with idiopathic thrombocytopenic
purpura. Blood 2003; 102: 4306-11.

Thank you for copying data from http://www.arastirmax.com